Posted by Michael Wonder on 15 Dec 2016
NICE publishes second appraisal consultation document for brentuximab vedotin
15 December 2016 - The appraisal consultation relates to the use of brentuximab vedotin to treat patients with CD30 positive, non-Hodgkin's lymphoma.
Brentuximab vedotin is not recommended, within its marketing authorisation, for treating CD30-positive Hodgkin lymphoma in adults with:
- relapsed or refractory disease after autologous stem cell transplant or
- increased risk of disease relapse or progression after autologous stem cell transplant or
- relapsed or refractory disease after at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy is not an option.
